Key Summary Points {#FPar1}
==================

The current state of the art and future perspectives of catheter ablation for the treatment of atrial fibrillation (AF) is reviewed and summarized.Catheter ablation is a well-established treatment option for patients with symptomatic AF and is more successful at maintaining stable sinus rhythm than antiarrhythmic drugs.Pulmonary vein isolation (PVI) is the treatment of choice for symptomatic patients with paroxysmal and persistent drug-refractory AF.Patients with persistent or long-standing persistent AF and with arrhythmia recurrence after a previous PVI procedure may benefit from additional ablation strategies, such as substrate modification of various forms or left atrial appendage isolation.New technologies and techniques, such as identification of AF sources and magnetic resonance imaging-guided substrate modification, are driving further improvements in the success rates of catheter ablation for selected patients and might help to further reduce arrhythmia recurrence.

Introduction {#Sec1}
============

Atrial fibrillation (AF), the most common arrhythmia worldwide, is associated with increased morbidity and mortality \[[@CR1], [@CR2]\]. Catheter ablation of AF has evolved from an investigational procedure to the most effective treatment option for symptomatic patients, supported by encouraging clinical outcome data \[[@CR2], [@CR3]\]. Catheter ablation for AF has been shown to be beneficial to patients with heart failure \[[@CR4]\] and offers a significant improvement in the quality of life \[[@CR5]\].

Multiple energy sources and a variety of ablation tools as well as different ablation strategies have been evaluated over the years \[[@CR6], [@CR7]\]. In this review, we summarize the state of the art of catheter ablation for AF and the future prospectives of this procedure.

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Patient Selection for Catheter Ablation and Recommendations According to Current Guidelines {#Sec2}
===========================================================================================

As demonstrated in a variety of published studies, the primary clinical benefit of catheter ablation of AF is improvement in the quality of life. Therefore, the primary selection criterion for AF ablation is the presence of symptoms, such as fatigue, palpitations and dyspnea. Current guidelines recommend that additional variables to be considered, including, among others, the presence of concomitant heart disease, obesity and sleep apnea, as these variables could result in a higher complication rate, as well as left atrial (LA) size, patient age and type of AF \[[@CR2], [@CR8]\].

Catheter ablation of AF is recommended as a second-line therapy for patients with symptomatic paroxysmal AF (PAF) or persistent AF for whom therapy with antiarrhythmic drugs (AADs) (Class I) has failed and for patients with long-standing-persistent AF with a Class IIb indication. Although invasive cardiac procedures involve the potential for life-threatening complications, long-term AAD therapy has been shown to be more commonly associated with considerable side effects compared to ablation (17 vs. 8%) \[[@CR9]\]. Thus, novel guidelines also address the important issue of AF ablation as a first-line strategy in patients with symptomatic PAF or persistent AF, prior to or in conjunction with Class I or III antiarrhythmic drug therapy (Class IIa) \[[@CR2], [@CR8]\].

Success of AF Ablation {#Sec3}
======================

The multiple-procedure success rate of pulmonary vein isolation (PVI) in patients with PAF after a 5-year follow-up period has been reported to be approximately 80%, falling to about 60% after 10 years \[[@CR10], [@CR11]\]. For patients with persistent AF, stable sinus rhythm (SR) after successful PVI was reported in 25% after a single procedure and in 68% after multiple procedures, during a median follow-up of approximately 7 years \[[@CR12]\].

However, estimation of the real success rate after catheter ablation of AF remains difficult due to inconsistencies in the definitions of procedural success and post-procedural recurrences, differences in post-procedural rhythm monitoring and differences in the analysis of outcomes after single or multiple procedures. To date, the electrophysiology community has defined AF recurrence as the occurrence of any symptomatic or asymptomatic atrial tachyarrhythmia after the procedure lasting for \> 30 s. Newer studies have presented a novel definition focusing on the AF burden, which may represent a more relevant parameter for risk stratification and efficacy assessment after AF ablation \[[@CR13], [@CR14]\].

First Step: PVI {#Sec4}
===============

The pulmonary veins (PVs) have been shown to be the main trigger source for AF \[[@CR15]\], and antral PVI as a stand-alone ablation strategy results in beneficial clinical outcomes as compared to medical therapy only \[[@CR2]\].

Ablation strategies beyond PVI have not reproducibly been shown to be superior to PVI-only strategies in both paroxysmal and persistent AF \[[@CR16]--[@CR18]\]. The prospective and randomized Alster-Lost-AF trial assessed the outcome of two index strategies---stand-alone PVI and the stepwise approach of PVI followed by a substrate-modification approach involving complex fractionated atrial electrogram (CFAE) ablation and the creation of linear lesions---in patients with symptomatic, persistent or long-standing persistent AF. At 12 months, there were no significant differences in terms of freedom from atrial tachyarrhythmias between these two treatment strategies \[[@CR16]\]. The CHASE-AF clinical trial compared arrhythmia-free survival between patients with persistent AF undergoing PVI only and those undergoing a stepwise approach consisting of CFAE ablation and additional creation of linear lesions. This analysis also demonstrated no benefit for the stepwise approach \[[@CR18]\]. Finally, the large multicenter STAR AF 2 trial compared PVI only and either PVI + CFAE ablation or PVI + creation of LA linear lesions as the index ablation strategy in patients with persistent AF; the results also did not demonstrate any benefit of the more complex ablation procedure \[[@CR19]\].

Based on these results and others, PVI currently remains the only established endpoint for both patients with PAF and those with persistent AF and, according to the current AF guidelines, ablation beyond PVI is not recommended for patients with PAF or persistent AF undergoing a first ablation attempt \[[@CR2], [@CR20], [@CR21]\].

Radiofrequency-Based AF Ablation---Still The Gold Standard? {#Sec5}
-----------------------------------------------------------

The most commonly used procedure for AF ablation is a point-by-point ablation via a single-tip catheter usually combined with a three-dimensional (3D) mapping system, and the most common energy source is radiofrequency (RF) \[[@CR15], [@CR22]\]. RF-based ablation in conjunction with an electro-anatomical mapping system (EAM) allows a significant reduction of fluoroscopy dosage and provides additional information, such as the LA activation pattern and LA voltage. Beyond that, this technology facilitates an optimized treatment of additional substrate, non-PV triggers or atrial tachycardia \[[@CR23]--[@CR25]\]. In general, a low complication rate is reported for RF-based catheter ablation, with the most common complications being pericardial effusion and tamponades and access-site complications, such as groin bleeding or arteriovenous fistula \[[@CR22]\]. Although several attempts have been made to optimize navigation properties and to improve tip-to-tissue contact using robotic navigation \[[@CR26]--[@CR28]\], manually guided RF ablation is still the most widely used procedure.

Most of the established EAM systems use point-by-point acquisition of electrograms from a roving catheter with or without multi-electrode mapping capability \[[@CR29], [@CR30]\]. To date, The Carto system (CARTO; Biosense Webster, Diamond Bar, CA, USA; Fig. [1](#Fig1){ref-type="fig"}) \[[@CR6], [@CR11]\] and the EnSite NavX™ system (Endocardial Solutions, St. Jude Medical, Inc., St. Paul, MN, USA) have been the most detailed systems based on experience. Recently, a new mapping system (Rhythmia; Boston Scientific, Cambridge, MA, USA) that uses a small basket array of 64 electrodes (IntellaMap Orion; Boston Scientific) has been introduced with the aim to rapidly obtain an ultra-high-resolution EAM \[[@CR31], [@CR32]\]. Some clinical studies have already reported that the Rhythmia system in conjunction with the Orion catheter enables the determination of a successful PVI, may simplify ablation of complex atrial arrhythmias and could assist understanding of new targets for AF ablation \[[@CR33]--[@CR35]\].Fig. 1Example of a left arterial voltage map acquired using the Carto system-guided high-density mapping in a posterior--anterior and anterior--posterior view, in a patient with atrial fibrillation recurrence after undergoing the pulmonary vein isolation (PVI) procedure. *LSPV* Left superior pulmonary vein, *LIPV* left inferior pulmonary vein, *RSPV* right superior pulmonary vein, *RIPV* right inferior pulmonary vein, *LAA* left atrial appendage, *MV* mitral valve

Despite improvements in mapping technologies, the achievement of contiguous, transmural and permanent lesions using RF-based ablation remains challenging. Current technology is mainly limited by tip-to-tissue contact and the rather long learning curve of the operators \[[@CR36], [@CR37]\]. However, PV reconnection remains a dominant factor in arrhythmia recurrence after an initially successful catheter ablation, irrespective of the ablation device applied, and is substantially attributable to insufficient lesion formation during the index procedure \[[@CR38]\]. Optimal lesion formation in RF-based ablation depends on a variety of procedural parameters, including power settings, catheter stability, ablation time, size of the catheter tip, temperature and cooling of the catheter tip and contact force (CF). Ablation using conventional catheters provides only limited information to predict sufficient lesion formation, such as diminution of the local electrogram or impedance drop.

The aim of recently developed CF-sensing technologies is to overcome, at least in part, these limitations. In clinical studies, the use of CF monitoring has been associated with improved procedural outcome, and low CF has been associated with acute procedural failure and sites of PV reconnection \[[@CR36], [@CR39]\]. However, improved clinical outcomes in CF-guided AF ablation has not been uniformly reproduced by other studies \[[@CR40], [@CR41]\].

The ablation index (AI) is a novel marker of ablation lesion quality which incorporates CF, power and time in a weighted formula. The formula has been recently integrated into the automated lesion tagging software (VisiTag) of the 3D EAM system Carto 3 V4 (Biosense Webster Inc.). Previous clinical studies have confirmed the correlation between AI and PV reconnection rates \[[@CR42]\] and reduced ablation duration \[[@CR43]\] and have also shown that a prospective use of fixed AI targets results in a low rate of PV reconnection and high clinical success rates \[[@CR44]\].

The limitations of catheter ablation using RF have led to further interest in the development of novel catheter designs and alternative energy sources for PVI. These include balloon-based ablation systems, such as the cryoballoon (CB) (ArcticFront; Medtronic, Inc., Minneapolis, MN, USA), the laserballoon (Heartlight™; CardioFocus, Marlborough, MA, USA), the RF Hot Balloon (Hayama Arrhythmia Institute, Kanagawa, Japan) and the "Globe" multi-electrode contact mapping and ablation system (Globe; Kardium Inc., Burnaby, BC, Canada).

CB-Based PVI {#Sec6}
------------

While RF-based PVI in combination with a 3D mapping system was long considered to be the "gold standard", the CB has emerged as the most commonly used alternative ablation tool for PVI and is now established as the second "gold standard" in patients with PAF in the current guidelines \[[@CR2], [@CR6]\] (Fig. [2](#Fig2){ref-type="fig"}).

CB-based AF ablation as a "single-shot" ablation modality is not only readily applicable and easy to learn, but is also, due to its "over-the-wire" strategy, a particularly safe tool. It is associated with a low incidence of major complications, specifically driven by a low number of pericardial effusions or tamponades \[[@CR45]\]. In addition, the incidence of phrenic nerve palsy, which is the most common balloon-associated complication, can be kept considerably low by implementing safety algorithms, such as phrenic nerve pacing and monitoring of the compound motor action potential \[[@CR6], [@CR45]\]. Furthermore, the incidence of PV stenosis is a rare finding in patients undergoing CB ablation and has only been mentioned in incidental case reports \[[@CR46], [@CR47]\].Fig. 2Example of a cryoballoon (*CB*)-based PVI in a right-anterior-oblique (*RAO*) view. The CB is located at the left-superior pulmonary vein (PV). Contrast medium shows total occlusion of this PV. *CS* Coronary sinus catheter, *OEP* esophageal temperature probe

Most data on CB ablation have been collected from patients suffering from PAF, with the data showing encouraging outcomes. The multicenter FIRE AND ICE trial, which prospectively randomized PAF patients to either RF- or CB-based PVI, demonstrated non-inferiority of CB ablation versus RF ablation in terms of efficacy and safety \[[@CR6]\].

However, the positive findings from recent analyses encourage the application of CB-based catheter ablation to patients with persistent AF also. The recently published Cryo4persistent study focused not only on the recurrence of AF after previous CB-based PVI but also on the symptoms, and demonstrated a significant improvement in patients' quality of life following CB ablation in those with persistent AF \[[@CR48]\]. These findings were confirmed by Mörtsell et al. who analyzed data from two large prospective registries (the AF Ablation Long-Term registry within the EURObservational Research Programme \[AFA EORP\] and the Swedish catheter ablation registry) \[[@CR49]\]. These authors reported a lower EHRA (European Heart Rhythm Association) score---a measure of AF-related symptoms---and a lower rate of continued antiarrhythmic drugs after CB-based AF ablation. These effects may not only have a positive impact on patients' quality of life, but also a positive impact on healthcare economics \[[@CR49]\].

Endoscopic Laserballoon-Based PVI {#Sec7}
---------------------------------

The endoscopic ablation system (EAS; CardioFocus) is a balloon-based ablation system that incorporates a titratable laser energy source and a miniature 2F endoscope that enables an endoscopic view into the target PV. The result is visually guided laserballoon ablation, which enables PVI under direct endoscopic---and thus direct visual---control. A number of smaller studies have demonstrated the feasibility of EAS-guided PVI with convincing acute efficacy and a favorable safety profile \[[@CR7], [@CR50]\]. In addition, 1-year clinical follow-up data from a prospective multicenter study in patients with PAF showed a single-procedure clinical success rate of 63% in patients not receiving anti-arrhythmic medication \[[@CR51]\]. These results are in agreement with those from an analysis performed by Dukkipati et al. who reported a 1-year success rate in patients off anti-arrhythmic drugs of 60% after multiple procedures \[[@CR52], [@CR53]\].

The second-generation balloon system Heartlight™ (Excalibur, CardioFocus), whose features include real-time balloon sizing for rapid engagement with all sizes and shapes of PV, has become commercially available, as has the recently introduced third-generation balloon system Heartlight™ X3, (CardioFocus), which provides an automated laser source rotation to prevent gaps between applications and to further reduce application and procedure times.

Future modifications of this system may include electrodes on the balloon surface to provide real-time electrical recordings.

RF Hotballoon-Based PVI {#Sec8}
-----------------------

The RF Hotballoon (Hayama Arrhythmia Institute, Kanagawa, Japan) consists of a compliant balloon (diameter 25--35 mm) that is introduced into and manipulated within the left atrium via a 13F steerable transseptal sheath. After verification of optimal PV-occlusion the inner fluid is heated up to 70--75 °C via an RF generator. The assessment of initial studies consisted of a promising acute efficacy in combination with a satisfying safety profile, although a potentially higher risk of PV-stenosis was discussed by the authors \[[@CR54]\]. In addition, some authors reported that a high rate of touch-up RF was required \[[@CR55], [@CR56]\].

Globe Multi-electrode Mapping and Ablation System {#Sec9}
-------------------------------------------------

The novel "Globe" multi-electrode array catheter ablation system, which consists of 16 ribs with 122 gold-plated electrodes, is both a diagnostic and an RF ablation tool. A first-in-man study confirmed the feasibility of this system for single-shot PVI. Detailed information from several electrodes may enable voltage mapping with substrate modification and rotor mapping \[[@CR57]\]. Further studies involving a larger number of patients are needed to show the efficacy of this ablation tool.

Catheter Ablation of AF Beyond PVI {#Sec10}
==================================

Pulmonary vein isolation is an effective treatment strategy for patients with symptomatic PAF, but the success rate of this strategy remains limited in patients with persistent and long-standing persistent AF \[[@CR2], [@CR58]\]. Additional ablation supplementary to PVI may be considered in patients with recurrent AF after the initial stand-alone PVI procedure or in patients who do not achieve restoration of stable sinus rhythm despite successful recurrent PVI \[[@CR2]\]. To improve the success rate of catheter ablation, ablation strategies beyond PVI might be applied to treat additional arrhythmogenic substrates. The most commonly used strategies are ablation of CFAE and/or the creation of additional linear lesions in the left or right atrium \[[@CR2]\].

Complex fractionated atrial electrograms, introduced by Nademanee et al. \[[@CR59]\], are "low voltage atrial electrograms" (ranging from 0.04 to 0.25 mV), that have fractionated electrograms composed of two or more deflections and/or have a perturbation of the baseline with continuous deflection of a prolonged activation complex". Nademanee et al. reported that ablation of CFAE was efficacious in restoring SR in patients with PAF as well as in those with persistent AF, with 87% of these patients being free of atrial arrhythmia recurrence after a mean follow-up of 839 ± 493 days \[[@CR59]\]. This ablation strategy has since been applied in numerous clinical studies, generally in addition to PVI. All of these studies share the observation of a potential reduction of AF recurrence after a single procedure compared to stand-alone PVI. However, this benefit is overshadowed by a higher incidence of postprocedural atrial tachycardias, increased mean procedure times, mean RF energy application times and lack of reproducibility \[[@CR16], [@CR60]\].

Another innovative ablation strategy has recently been proposed by Narayan et al. \[[@CR61]\] who hypothesized that ablation of AF drivers (so-called rotors or focal impulses) might result in improved and longer arrhythmia-free survival in patients with highly symptomatic PAF or persistent AF than would ablation of pulmonary and non-pulmonary vein triggers. To test this hypothesis, the authors conducted the CONFIRM trial (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation), which enrolled 92 patients with highly symptomatic PAF or persistent AF in a two-arm 1:2 design with ablation of AF sources (Focal Impulse and Rotor Modulation \[FIRM\]-guided) followed by conventional ablation, mainly PVI (*n* = 36), or conventional ablation alone (*n* = 71; FIRM-blinded). Analysis of the data revealed that FIRM ablation at patient-specific sources could acutely terminate or slow the AF cycle length and improve clinical outcomes \[[@CR61]\]. While the initial results and long-term data of the CONFIRM trial were promising, subsequent studies have shown inconsistent results \[[@CR62]\]. Despite high operator-dependent variability, the fact that active and passive sources cannot be discriminated by this technology might play an additional role regarding the efficacy of AF driver elimination during FIRM-guided ablation \[[@CR63], [@CR64]\].

Electrographic flow (EGF) mapping has recently been introduced as a novel technology for the identification and characterization of AF sources in humans. Bellmann et al. demonstrated that EGF is the first method to have the potential to identify active AF sources during AF ablation and to be able to discriminate these from passive rotational phenomena, thereby possibly allowing for improved guidance of the AF ablation procedure \[[@CR65], [@CR66]\].

AF analysis using a non-invasive body surface mapping technique has also been shown to be able to identify reentrant and focal sources that play a potential role in driving and perpetuating AF. This non-invasive mapping-guided ablation strategy has been shown to be effective especially in patients with persistent AF \[[@CR67], [@CR68]\]. In 2017, Knecht et al. sought to evaluate the utility of non-invasive electrocardiogram (ECG) mapping as a practical tool prior to catheter ablation of persistent AF \[[@CR68]\]. These authors performed ECG mapping (ECVUE™; CardioInsight Technologies, Medtronic, Dublin Ireland) in 118 patients with the aim to detect AF drivers. The CardioInsight Technologies noninvasive 3D mapping system collects chest ECG signals and merges these signals with computed tomography (CT) scan data in order to produce and display simultaneous biatrial maps that enable visualization of AF drivers. During the study, targeted drivers were ablated followed by PVI and left atrium linear lesion ablation. In the majority of patients, AF termination (into SR or atrial tachycardia) could be achieved only by ablation of the detected drivers, and ablation of these drivers resulted in favorable AF-free survival at the 1-year follow-up \[[@CR68]\].

Local voltage abnormalities are also used as a surrogate for diseased cardiac tissue, such as atrial fibrosis. Recent studies using late gadolinium enhancement cardiac magnetic resonance imaging (MRI) have demonstrated that this diagnostic modality can facilitate the identification of structural changes in atrial tissue, thereby improving our understanding of the pathophysiology of AF. Moreover, extensive LA tissue fibrosis has shown to predict poor outcome after catheter ablation of AF \[[@CR69]\]. Furthermore, imaging of atrial fibrosis using MRI has evolved to a tool that can be used to improve clinical outcomes after AF ablation by allowing a patient-specific, individualized approach \[[@CR70]\]. In the ongoing DECAAF II study, patients will be randomized to receive conventional PVI or PVI + fibrosis-guided ablation. The primary outcome is defined as recurrence of AF. Results are expected to be released in July 2021 and will give further insights into the impact of fibrosis on AF ablation outcomes.

The left atrial appendage (LAA) has also been identified as a source of atrial arrhythmias as it can potentially trigger and sustain AF. Recently, the BELIEF trial showed that an electrical isolation of the LAA in addition to PVI could increase clinical success rates \[[@CR71]\]. This same result was also reported by other investigators \[[@CR72]\]. In addition to a more distinct ablation along the base of the LAA aiming at isolation \[[@CR71], [@CR72]\], some operators achieve LAA isolation by wide-area LA ablation with LA lines in addition to PVI \[[@CR73]\]. Nevertheless, it should be kept in mind that isolation of the LAA in these cases has been shown to be associated with a significantly increased risk for LAA thrombus formation and thromboembolic events \[[@CR74], [@CR75]\]. Therefore, the indication for LAA isolation should be reserved for patients with highly symptomatic, long-standing persistent AF or patients with recurrent atrial tachyarrhythmia recurrence.

Future Perspectives in AF Ablation {#Sec11}
==================================

The aim of novel technologies is to improve the safety profile and clinical outcomes of AF ablation, reduce procedure time and fluoroscopy dosages, shorten the learning curve of the operators and possibly also help to improve our still limited understanding of the underlying mechanism of AF, especially of persistent and long-standing persistent AF.

As mentioned in the above text, RF energy and cryoenergy are to date the two most widely used energy modalities for the treatment of cardiac arrhythmias. Thermal ablation, however, may lead to severe complications, such as PV stenosis and esophageal ulceration, despite several improvements to these technologies and applied safety algorithms \[[@CR22], [@CR45]\]. A novel technology, irreversible electroporation (IRE), may overcome these limitations. With IRE, a direct current is applied and the generated high electrical field produces pores in the phospholipid membranes of the cells, which leads to an irreversible breakdown of membrane structure and function and ultimately cell death. The first animal studies confirmed a significant effect of IRE on cardiac cells and therefore lesion formation as well as the safety of the system on surrounding intra- and extracardiac structures \[[@CR76], [@CR77]\]. In vivo, clinical experiments are required to investigate the clinical implication of these observations.

A "High Power, Short Duration" strategy (HPSD) has recently been propagated as a further step towards the improvement of lesion quality during RF ablation in patients with symptomatic AF. Although this strategy is not absolutely new, it has been shown that HPSD ablation creates wider but more shallow lesions ex vivo as well as in vivo \[[@CR78], [@CR79]\], which could avoid damage to adjacent structures, such as the esophagus or the phrenic nerve, during ablation procedures. The feasibility and safety of HPSD strategy during AF ablation has already been confirmed in a clinical setting \[[@CR80]\]. Additional advantages of this procedure are the possible decreases in procedure and fluoroscopy times, particularly when novel catheter technologies, such as the QDOT-FAST catheter, are used \[[@CR81]\].

The HELIOSTAR RF Balloon Ablation Catheter (Biosense Webster, Inc.) has recently been introduced. It conforms to any pulmonary vein anatomy and has ten irrigated electrodes, which allows the operator to deliver different levels of energy during ablation. The device is compatible with the Biosense Webster CARTO 3 Mapping System (Biosense Webster, Inc.) and can therefore reduce radiation exposure during an ablation procedure. Its feasibility and safety profile as well as the clinical impact for the treatment of AF are still under evaluation. The STELLAR study (Safety and Effectiveness of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic paroxysmal Atrial Fibrillation) is a pivotal, prospective, multicenter, single-arm clinical evaluation of the multi-electrode RF-balloon. Data are expected to be released 2021.

Two other balloon ablation systems are under study, namely the POLARx cryo-ablation catheter (Boston Scientific) and the Apama RF hot balloon (Boston Scientific).

KODEX-EPD (KODEX-EPD™; EPD Solutions, Philips, Eindhoven, The Netherlands) is a novel cardiac imaging system providing electroanatomical 3D-visualization for guiding the treatment of PVI or complex atrial arrhythmias. It utilizes wide-band dielectric sensing and a unique bending of electric fields technology to generate high-resolution images of the cardiac anatomy. The acquisition process involves contact and non-contact mapping maneuvers using any type of diagnostic or ablation catheter. Anatomical mapping of the LA using KODEX-EPD bears the potential to create CT-like images without the need for additional periprocedural fluoroscopy \[[@CR82]\]. In addition to the creation of a 3D anatomical shell, the KODEX-EPD system provides the opportunity to visualize a cardiac chamber in a flattened panoramic view with the PANO view mode (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3The KODEX-EPD system provides the opportunity to visualize a cardiac chamber in a flattened panoramic view with the PANO view mode (posterior--anterior view) in addition to creating a three-dimensional map

The results of the UNCOVER-AF (Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation) trial have only very recently been published \[[@CR83]\]. This prospective, non-randomized trial was conducted at 13 centers in Europe and Canada and examined the use of a novel, non-contact imaging and mapping system that uses ultrasound to reconstruct atrial chamber anatomy and measures the timing and density of dipolar, ionic activation of the myocardium to guide ablation of atrial arrhythmias in patients with persistent AF. The results confirmed the feasibility and safety of this novel ultrasound imaging and charge density mapping system during AF ablation. The analysis also demonstrated a AF-free survival of 73 and 93% after a single and second procedure after 12 months, respectively \[[@CR83]\].

Conclusions {#Sec12}
===========

Catheter ablation is a well-established treatment option for patients with symptomatic AF and more effective at maintaining SR than antiarrhythmic drugs. Currently, the most effective technique for AF ablation is circumferential isolation of the PVs, irrespective of AF type. RF-based and CB ablation are equally effective in patients with PAF. Patients with persistent or long-standing persistent AF and with recurrence after an index ablation procedure might benefit from additional and more extensive ablation strategies. Novel technologies, such as KODEX-EPD and IRE, as well as other emerging techniques have the potential to improve the success rates of catheter ablation for select patient groups.
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